JP6789112B2 - Ｃｄ４＋ｔリンパ球の検出、調製および枯渇のための向上した方法 - Google Patents

Ｃｄ４＋ｔリンパ球の検出、調製および枯渇のための向上した方法 Download PDF

Info

Publication number
JP6789112B2
JP6789112B2 JP2016516134A JP2016516134A JP6789112B2 JP 6789112 B2 JP6789112 B2 JP 6789112B2 JP 2016516134 A JP2016516134 A JP 2016516134A JP 2016516134 A JP2016516134 A JP 2016516134A JP 6789112 B2 JP6789112 B2 JP 6789112B2
Authority
JP
Japan
Prior art keywords
cells
complex
peptide
epitope
motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016516134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527875A5 (enExample
JP2016527875A (ja
Inventor
サン−レミ，ジャン−マリー
カルリエ，ヴァンサン
バンデル・エルスト，リュク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imcyse SA
Original Assignee
Imcyse SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse SA filed Critical Imcyse SA
Publication of JP2016527875A publication Critical patent/JP2016527875A/ja
Publication of JP2016527875A5 publication Critical patent/JP2016527875A5/ja
Application granted granted Critical
Publication of JP6789112B2 publication Critical patent/JP6789112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016516134A 2013-05-28 2014-05-27 Ｃｄ４＋ｔリンパ球の検出、調製および枯渇のための向上した方法 Expired - Fee Related JP6789112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1309469.3 2013-05-28
GBGB1309469.3A GB201309469D0 (en) 2013-05-28 2013-05-28 Detection of CD4+ T lymphocytes
PCT/EP2014/060994 WO2014191432A1 (en) 2013-05-28 2014-05-27 Improved method for the detection, preparation and depletion of cd4+ t lymphocytes

Publications (3)

Publication Number Publication Date
JP2016527875A JP2016527875A (ja) 2016-09-15
JP2016527875A5 JP2016527875A5 (enExample) 2018-08-16
JP6789112B2 true JP6789112B2 (ja) 2020-11-25

Family

ID=48784761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516134A Expired - Fee Related JP6789112B2 (ja) 2013-05-28 2014-05-27 Ｃｄ４＋ｔリンパ球の検出、調製および枯渇のための向上した方法

Country Status (6)

Country Link
US (2) US20160091492A1 (enExample)
EP (1) EP3004137B1 (enExample)
JP (1) JP6789112B2 (enExample)
ES (1) ES2868423T3 (enExample)
GB (1) GB201309469D0 (enExample)
WO (1) WO2014191432A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
RU2615460C2 (ru) 2010-11-25 2017-04-04 Имнейт Сарл Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов. используемых для генной терапии или генной вакцинации
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
EP3419656A4 (en) * 2016-02-22 2019-10-30 Oceanside Biotechnology NEOANTIGEN COMPOSITIONS AND METHODS FOR USE THEREOF IN IMMUNOOTHERAPY
KR20240015731A (ko) 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
US12480958B2 (en) * 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004103A1 (en) 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4886782A (en) 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
EP0550599B1 (en) 1990-09-27 2003-04-23 Tripep AB Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0623168B1 (en) 1991-10-16 2009-09-30 Merck Patent GmbH T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5824315A (en) 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
DE69730038T2 (de) 1996-08-16 2004-11-25 The President And Fellows Of Harvard College, Cambridge Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
US20030152581A1 (en) 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
CA2350911A1 (en) 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
EP2333065B1 (en) 2000-01-28 2017-03-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MHC class II restricted T cell epitopes from the cancer antigen NY ESO-1
GB0006437D0 (en) 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
AU2001272491A1 (en) 2000-06-26 2002-01-08 Smithkline Beecham Biologicals (S.A.) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20040173778A1 (en) 2001-05-30 2004-09-09 Roncarolo Maria Grazia Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
EP1432738B1 (en) 2001-10-03 2009-03-04 Unilever N.V. Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2003072731A2 (en) 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
CN103073620B (zh) 2002-09-12 2014-12-10 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
WO2005012502A2 (en) 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
GB0324265D0 (en) 2003-10-16 2003-11-19 Medical Res Council Peptide
WO2005042575A2 (en) 2003-10-30 2005-05-12 Pharmexa A/S Method for down-regulation of vegf
EP2332971B1 (en) 2004-06-17 2016-02-17 MannKind Corporation Epitope analogs
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
WO2007027954A2 (en) 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
FR2898275B1 (fr) 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
PT2476435T (pt) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
CA2700618A1 (en) 2007-09-27 2009-04-02 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
WO2009101204A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
AU2009214041A1 (en) 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
WO2009101206A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
WO2009101201A2 (de) 2008-02-15 2009-08-20 Chemetall Gmbh Mischungen aus metallhydriden und ionischen flüssigkeiten und verwendungen solcher mischungen
WO2009106073A2 (en) 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CA2756996C (en) 2009-04-01 2018-12-11 University Of Miami Vaccine compositions and methods of use thereof
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
CN103002909B (zh) 2010-03-29 2016-06-29 国家科学研究中心 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
WO2011147894A1 (en) 2010-05-25 2011-12-01 Forschungsverbund Berlin E.V. Chimeric mhc class ii proteinpeptide
RU2615460C2 (ru) 2010-11-25 2017-04-04 Имнейт Сарл Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов. используемых для генной терапии или генной вакцинации
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
CN104271148A (zh) 2012-02-15 2015-01-07 洛桑聚合联合学院 红细胞结合性治疗剂
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201319160D0 (en) 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20240015731A (ko) 2016-04-19 2024-02-05 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드

Also Published As

Publication number Publication date
EP3004137B1 (en) 2021-03-17
EP3004137A1 (en) 2016-04-13
US20160091492A1 (en) 2016-03-31
ES2868423T3 (es) 2021-10-21
US11226332B2 (en) 2022-01-18
WO2014191432A1 (en) 2014-12-04
JP2016527875A (ja) 2016-09-15
GB201309469D0 (en) 2013-07-10
US20200103407A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP6789112B2 (ja) Ｃｄ４＋ｔリンパ球の検出、調製および枯渇のための向上した方法
CN113474840B (zh) 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统
US20220119778A1 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
CN108289941B (zh) 用于消除对治疗剂的免疫应答的改进的方法和化合物
US20210188913A1 (en) Modified epitopes for boosting cd4+ t-cell responses
JP2022513021A (ja) 向上した酸化還元酵素モチーフを有する免疫原性ペプチド
JP2019514895A (ja) 新規な免疫原性ＣＤ１ｄ結合ペプチド
CN119698427A (zh) 用于预测hla ii类特异性表位和表征cd4+ t细胞的方法和系统
KR20200055136A (ko) Th1 및 Th2를 자극하는 다가 항원 (MULTIVALENT ANTIGENS STIMULATING TH1 AND TH2)
HK40064028A (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
HK40034610A (en) Modified epitopes for boosting cd4+ t-cell responses
HK40062113B (zh) 用於预测hla ii类特异性表位及表徵cd4+ t细胞的方法和系统
HK40062113A (en) Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
HK1252695B (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
HK40038219A (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
HK40038219B (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160128

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20160122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180424

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190418

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190418

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190514

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190604

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190611

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190802

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200107

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20200109

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200707

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20200901

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201006

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201102

R150 Certificate of patent or registration of utility model

Ref document number: 6789112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees